A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500746-16-00

Acronym

81201887MDG2001

Enrollment

118

Registered

2023-07-17

Start date

2023-08-11

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geographic Atrophy

Brief summary

Change in square root GA lesion area in the study eye measured on fundus autofluorescence (FAF)

Interventions

DRUGJNJ-81201887

DRUGPlacebo to match Prednisone 20mg

DRUG5mg

DRUGPrednison acis 5 mg

DRUGKenacort-A 40

DRUGsuspensie voor injectie 40 mg/ml

DRUGPrednison acis 20 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in square root GA lesion area in the study eye measured on fundus autofluorescence (FAF)	—

Countries

Belgium, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026